Evidence map›Paper›PMID 33120755›Full record

ArticleMedicine2020

Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast: A case report.

Yonglin Zhang, Chao Liu, Chaoting Zheng, Qiaozhen Ren, Qimin Wang, Xinyi Gao, Yushuang He, Jierong Wu, Guanglei Chen, Xuelu Li and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Multifocal diffuse large cell neuroendocrine carcinoma of the colon.Journal of clinical and translational research · 2022
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Yonglin ZhangDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning.
Chao LiuDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning.
Chaoting ZhengDepartment of Nursing, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou.
Qiaozhen RenThe sixth people's hospital of Dalian, Dalian, Liaoning.
Qimin WangDepartment of Pathology, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, P.R. China.
Xinyi GaoDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning.
Yushuang HeDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning.
Jierong WuDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning.
Guanglei ChenDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning.
Xuelu LiDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning.
Zhenhai MaDepartment of Breast Disease and Reconstruction Center, Breast Cancer Key Lab of Dalian, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning.
Second Affiliated Hospital of Dalian Medical University · CNAffiliated Hospital of Guizhou Medical University · CNSeventh People's Hospital of Dalian · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationalePoorly differentiated neuroendocrine carcinoma of the breast is a rare cancer with poor prognosis. There is no standard treatment for the disease. Neoadjuvant therapies and surgery are considered to be the main treatment when the tumor diameter is greater than 5.0 cm. Neoadjuvant therapies include chemotherapy and endocrine therapy. However, the effect of neoadjuvant endocrine therapy is not clear in the disease. PATIENT CONCERNS: In August 2014, a 28-year-old premenopausal woman noted a mass that was approximately 3.0 cm*2.0 cm in size on her right breast with pain. Subsequently, the mass has been always increasing significantly. In August 2015, the mass was approximately 7.0 cm*5.0 cm in size, accompanied by pain, no nipple retraction and discharge, no orange peel-like skin changes, and no dimples. In addition, she had no salient past history. DIAGNOSES: Histopathological examinations by a biopsy with a thick needle (hollow needle) and surgical resection confirmed poorly differentiated neuroendocrine carcinoma of the right breast.

interventionsFirst and remarkably, she underwent 3 months of neoadjuvant endocrine therapy (goserelin once every 28 days, and letrozole 10 mg every day). Then, she underwent surgery - stage I breast reconstruction by using prosthesis. Adjuvant endocrine therapy has been used since the operation. OUTCOMES: According to response evaluation criteria in solid tumors 1.1, the tumor was shrunk by 78.87% after neoadjuvant endocrine therapy. No salient complications were observed. We have followed her for 48 months, and there are no signs of recurrence and metastasis. LESSONS: Poorly differentiated neuroendocrine carcinoma of the breast is rare and has a poor prognosis. Currently, there is no standard treatment for this disease. Studies show estrogen receptor and progesterone receptor of neuroendocrine carcinoma of the breast are often highly expressed. In the case, it can be observed that estrogen receptor and progesterone receptor are highly expressed. Therefore, neoadjuvant endocrine therapy may be considered in neuroendocrine carcinoma of the breast when the mass is large and the patient refuses neoadjuvant chemotherapy. We hope to provide an attractive evidence for neoadjuvant endocrine therapy of neuroendocrine carcinoma of the breast. However, more cases are still being needed for research.

Indexed as

AdultAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBreast NeoplasmsCarcinoma, NeuroendocrineFemaleGoserelinHumansLetrozoleNeoadjuvant TherapyAntineoplastic Agents, HormonalAromatase InhibitorsGoserelinLetrozole

Identifiers

PMID33120755
PMCPMC7581040
OpenAlexW3093921533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.